At Bard Biopsy Systems we are committed to helping physicians deliver uncompromised care for every patient - from breast biopsy to therapy. We understand the challenges physicians face in delivering superior care for their patients at all stages of treatment. Our technology, service and product development is directed toward finding solutions to these challenges that make it easier and more efficient for physicians to take patient care to a higher level.

The 2010 acquisition of SenoRx completed a portfolio of biopsy, tissue marker, and therapy devices unmatched in the field.

This broad line of category leading products ensures that physicians always have the best product for the challenge before them - without the need to compromise. Our customers can confidently enjoy the benefits of partnering with a single, trusted source, secure in knowing that no matter which Bard product they choose, they are choosing the best in its class.

Bard Biopsy Systems proudly supports the breast cancer community through sponsorship of activities such as the American Cancer Society's "Making Strides Against Breast Cancer Walk."

Based in Tempe, Arizona, Bard Biopsy Systems has sales operations throughout North America, Europe, Australia, Latin America and Asia. Bard Biopsy Systems is a business unit of Bard Peripheral Vascular, Inc., one of five divisions of C. R. Bard, Inc. For over 100 years, C. R. Bard has committed its resources to creating innovative products and services that meet the needs of healthcare providers and patients.

Hologic is a market leader in mammography and breast biopsy, breast magnetic resonance imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging, and molecular diagnostic products including human papillomavirus (HPV) testing and reagents for a variety of DNA and RNA analysis applications.

We are proud of our achievements and conscious of the responsibility that our leadership position brings with it. We believe that the health issues facing women today deserve and demand the singular dedication of a passionate company. Our core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health

With a growing presence in cardiology, oncology, and women’s health, we focus on the fundamental health problems with which people are confronted, such as congestive heart failure, lung and breast cancers and coronary artery disease. Our focus is to deliver value throughout the complete cycle of care: from disease prevention to screening and diagnosis through to treatment, monitoring and health management. Philips is dedicated to making an impact wherever care happens, within the hospital - critical care, emergency care and surgery – and, as importantly, in the home.

The Benchmark. Faxitron is the industry standard in cabinet x-ray systems for point-of-care specimen radiography, research imaging and irradiation, and NDT applications.

Global Experience. Our installed base numbers more than 6,000 systems in medical facilities and scientific and industrial laboratories around the world.

Innovative Technology. Faxitron's leading edge technology in x-ray sources and detectors continues to meet the evolving needs of our customers.

people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems. Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world.

Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries.

• FDA, Canadian and European market approvals

• 12 min. examination time - 5 min. review time

• Integrates with all breast ultrasound imaging and PACS systems

• Delivers a fully documented, quality controlled and reproducible breast screening examination

• 2D Cine Lesion Detection

• 3D Lesion Assessment

• Published Multi-Center Peer-Reviewed Screening Trial, European Radiology